Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

1,105 923

Total assets 4,970 4,762

Total debt 2,004 2,080

Shareholders' equity 2,158 1,866

Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the quarter ended June 30, 2008, and (2) the calculation of EBITDA for each period presented.

Adjusted earnings per share and EBITDA are non-GAAP financial measures. The Company is providing this information, however, because it believes that such information is useful to both management and investors in that it facilitates analysis by both management and investors in evaluating the Company's performance and trends. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with GAAP.

Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data

(in millions, except per share data)

Three Months Ended June 30, 2008

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $675 - $675

Alliance and development revenue 93 (53)(f) 40

Other revenue 11 (6)(b) 5

Total revenues 779 (59) 720

Costs and expenses:

Cost of sales 353 (65)(b),(c),(d) 288

Selli
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... Scottsdale, AZ (PRWEB) July 11, 2014 ... medicine device company specializing in the soft tissue ... SureLock All-Suture Anchor System for surgeries involving the ... predictable fixation through a novel, inserter-controlled deployment method. ... lead to partial deployment, anchor pull-out, or anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Enrollment in First Cohort --, SAN DIEGO, ... today announced that the Company,has completed enrollment of ... trial,to assess the safety and tolerability of new ... The trial is expected to dose up to ...
... (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused ... Mr.,Pedro Granadillo was appointed on October 16, 2007 ... is a highly-respected pharmaceutical industry,leader with over 30 ... and quality assurance. "We are pleased to ...
... AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... will present to and meet with investors at,the CIBC ... New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), WHEN: ... begins promptly at 10:20 a.m. (Eastern Time), 9:20 a.m. ...
Cached Biology Technology:Nventa updates progress of cervical dysplasia trial with new HspE7 2Nventa updates progress of cervical dysplasia trial with new HspE7 3Nventa updates progress of cervical dysplasia trial with new HspE7 4Nventa updates progress of cervical dysplasia trial with new HspE7 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 3
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Blame it on the astrocytes 2
... Energy,s Brookhaven National Laboratory have identified two promising candidates ... cause of ailments ranging from colds to gastrointestinal disorders ... Letters , a journal of the Federation of European ... of compounds to determine which might block the effects ...
... in metabolic pathways as a result of oncogenes that ... 2) works as a "master gene" that turns on ... to protect the lungs from variety of air pollutants ... at the Johns Hopkins Bloomberg School of Public Health ...
... CATransport proteins are responsible for moving materials such as ... which seals and protects all living cells, to the ... be used to fuel growth or to respond to ... cell. Measuring the activity of transporter proteins in a ...
Cached Biology News:Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3Hijacking stress response in cancer 2Breakthrough: Sensors monitor cells at work 2
PSMD1 Antibody...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
... The high-performance triple quadrupole 1200L ... in today's cost-conscious environment - incorporating ... solutions for all liquid chromatography analytical ... (API) interface and the Transmission Quadrupole ...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: